INM
InMed Pharmaceuticals Inc.
NASDAQ · Healthcare · Biotechnology · CA
$1.38
+3.76%Year over year
Reported trailing growth
- Revenue
- -18.3%
- EBITDA
- -22.2%
- EBIT
- -22.8%
- EPS
- —
- Free cash flow
- -28.3%
- Operating cash flow
- -28.3%
Forward estimates
Based on analyst estimates
- Revenue
- -74.3%
- EBITDA
- —
- EPS
- +51.6%
Three-year CAGR
- Revenue
- +65.5%
- EBITDA
- -2.7%
- EBIT
- +2.7%
- Net income
- -6.3%
- EPS
- +58.5%
- Free cash flow
- -11.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026